艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ABBV 艾伯维公司

休市中 05-03 16:00:00 EDT

163.79

+2.98

+1.85%

盘后163.79

+0.000.00%

19:57 EDT

最高164.25	最低160.74	成交量585.01万
今开161.16	昨收160.81	日振幅2.18%
总市值2,900亿	流通市值2,894亿	总股本17.71亿
成交额9.55亿	换手率0.33%	流通股本17.67亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ABBV","market":"US","secType":"STK","nameCN":"艾伯维公司","latestPrice":163.79,"timestamp":1714766400000,"preClose":160.81,"halted":0,"volume":5850102,"hourTrading":{"tag":"盘后","latestPrice":163.79,"preClose":163.79,"latestTime":"19:57 EDT","volume":1041144,"amount":170488756.8419,"timestamp":1714780645691},"delay":0,"floatShares":1766775109,"shares":1770646983,"eps":2.72,"marketStatus":"休市中","marketStatusCode":7,"change":2.98,"latestTime":"05-03 16:00:00 EDT","open":161.16,"high":164.25,"low":160.74,"amount":954538620.4473,"amplitude":0.021827,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.72,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714982400000},"adr":0,"adjPreClose":160.81,"adrRate":0,"dividendRate":0.036999,"preHourTrading":{"tag":"盘前","latestPrice":161.4,"preClose":160.81,"latestTime":"09:28 EDT","volume":1866,"amount":300580.15025999997,"timestamp":1714742885537},"postHourTrading":{"tag":"盘后","latestPrice":163.79,"preClose":163.79,"latestTime":"19:57 EDT","volume":1041144,"amount":170488756.8419,"timestamp":1714780645691},"volumeRatio":0.8727355228093829},"requestUrl":"/m/hq/s/ABBV/","defaultTab":"news","newsList":[{"id":"2432219273","title":"艾伯维公司2024财年第一财季实现净利润13.59亿美元，同比增加496.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432219273","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432219273?lang=zh_cn&edition=full","pubTime":"2024-05-04 15:26","pubTimestamp":1714807591,"startTime":"0","endTime":"0","summary":"3月31日，艾伯维公司公布财报，公告显示公司2024财年第一财季净利润为13.59亿美元，同比增加496.05%；其中营业收入为123.10亿美元，同比增加0.70%，每股基本收益为0.77美元。从资产负债表来看，艾伯维公司总负债1,408.27亿美元，其中短期债务101.96亿美元，资产负债比为1.00，流动比率为0.94。机构评级：截至2024年3月31日，当前有24家机构对艾伯维公司目标价做出预测，其中目标均价为184.04美元，其中最低目标价为161.00美元，最高目标价为207.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050415263487d0bf40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050415263487d0bf40&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432663604","title":"艾伯维下跌1.24%，报159.71美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432663604","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2432663604?lang=zh_cn&edition=full","pubTime":"2024-05-02 21:48","pubTimestamp":1714657705,"startTime":"0","endTime":"0","summary":"5月2日，艾伯维(ABBV)盘中下跌1.24%，截至21:48，报159.71美元/股，成交5459.6万美元。财务数据显示，截至2024年03月31日，艾伯维收入总额123.1亿美元，同比增长0.7%；归母净利润13.69亿美元，同比增长472.8%。大事提醒：4月29日，艾伯维获巴克莱下调目标价至187美元，最新评级Overweight。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/05/02214840511459.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431836845","title":"BUZZ-券商观点：艾伯维的 Humira 将是 2025 年前的主要争论焦点","url":"https://stock-news.laohu8.com/highlight/detail?id=2431836845","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2431836845?lang=zh_cn&edition=full","pubTime":"2024-04-29 18:30","pubTimestamp":1714386636,"startTime":"0","endTime":"0","summary":"** 美国银行全球研究 称，虽然第一季度财报后的股价回调 \"过度\"，但 2024 年的前景不足以抵消 2025 年因 Stelara 生物仿制药和 Humira 侵蚀的影响而产生的担忧。** BMO 指出，尽管该公司有能力对 Humira 的下滑做出相应规划，但 ABBV 美容业务近期的疲软意味着美国以外地区的不利因素可能比之前预期的更为持久。** Truist Securities 称，考虑到公司产品组合和产品线的长期增长，对Humira的担忧是过度的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430075882","title":"美国生物技术公司艾伯维 一季度调整后每股收益2.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430075882","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430075882?lang=zh_cn&edition=full","pubTime":"2024-04-27 06:35","pubTimestamp":1714170908,"startTime":"0","endTime":"0","summary":"美国生物技术公司艾伯维一季度调整后每股收益2.31美元，预期2.23美元；净营收123.1亿美元，预期119.4亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404270647158b58b0da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404270647158b58b0da&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430444781","title":"嗡嗡声--美国股票走势-雪佛龙、英特尔、Alphabet","url":"https://stock-news.laohu8.com/highlight/detail?id=2430444781","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430444781?lang=zh_cn&edition=full","pubTime":"2024-04-27 02:04","pubTimestamp":1714154695,"startTime":"0","endTime":"0","summary":"        *      个股异动的 Eikon 搜索字符串：[STXBZ］        *      The Day Ahead 新闻通讯：          *      The Morning News Call时事通讯：      4月26日 - 周五华尔街主要股指上扬，原因是 Alphabet 公司强劲的季度业绩推动其市值超过 2 万亿美元，多数大型成长股上涨，而通胀数据与预期持平也平息了加息的不安情绪。美东时间13:37，道琼斯工业平均指数  上涨0.65%，报38,331.51点。标准普尔500指数  上涨1.29%，报5,113.68点；纳斯达克综合指数  上涨2.31%，报15,972.848点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"1124556462","title":"艾伯维“新动能”势头迅猛，上调2024年EPS预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1124556462","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/1124556462?lang=zh_cn&edition=full","pubTime":"2024-04-26 21:20","pubTimestamp":1714137631,"startTime":"0","endTime":"0","summary":"一季度的总销售额达到123亿美元，同比小幅增长，高于119亿美元的普遍预测。","market":"us","thumbnail":"https://static.tigerbbs.com/bea2b509b27ecfae8b061ae58d521a91","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/bea2b509b27ecfae8b061ae58d521a91"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"db281c116d914585a115ec9827470da2","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1112362.html","is_publish_highlight":true,"gpt_icon":1},{"id":"2430501278","title":"艾伯维因 Skyrizi 销售强劲而上调年度利润预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2430501278","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430501278?lang=zh_cn&edition=full","pubTime":"2024-04-26 19:36","pubTimestamp":1714131396,"startTime":"0","endTime":"0","summary":"艾伯维和其投资者一直关注较新的免疫学药物Skyrizi和Rinvoq的销售情况，以抵消Humira对销售额的侵蚀--Humira是全球销量最大的药物，直到去年它失去了独家代理权，并出现了近似的仿制药。Skyrizi 的销售额为 20.1 亿美元，超过了预期的 19.4 亿美元，而 Rinvoq 的销售额为 10.9 亿美元，略高于预期的 10.6 亿美元。本季度，Humira 的销售额下降了近 36%，为 22.7 亿美元，与预期的 22.8 亿美元基本一致。本季度Imbruvica的销售收入为8.38亿美元，高于预期的7.44亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430251469","title":"Cigna 将在专科药房提供共付额为 0 美元的 Humira 竞争产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2430251469","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430251469?lang=zh_cn&edition=full","pubTime":"2024-04-26 04:30","pubTimestamp":1714077004,"startTime":"0","endTime":"0","summary":"Cigna表示，它将在其Accredo药房储备勃林格殷格翰、梯瓦  和Alvotech  等制药商生产的高浓度和低浓度Humira生物仿制药。尽管去年有九种生物仿制药在美国上市，但艾伯维仍占据了超过 98% 的 Humira 市场份额。艾伯维的高浓度版 Humira 占其在美国销售额的近 90%。Cigna 表示，这些生物仿制药的价格将比 Humira 每月 6922.62 美元的上市价格低约 85%，它已与生产商及其分销商 Quallent 达成协议，将自付费用降至 0 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430400210","title":"更新版 1-重发-研究发现艾伯维的皮肤病药物比 Regeneron 的 Dupixent 更有效","url":"https://stock-news.laohu8.com/highlight/detail?id=2430400210","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430400210?lang=zh_cn&edition=full","pubTime":"2024-04-25 20:44","pubTimestamp":1714049048,"startTime":"0","endTime":"0","summary":"     路透社4月25日 - 艾伯维  周四称，在一项晚期头对头研究中，发现 其治疗一种炎症性皮肤病的药物Rinvoq比Regeneron Pharmaceuticals  和赛诺菲  的Dupixent更有效 。研究显示，在治疗16周后，Rinvoq帮助19.9%的患者同时实现了近乎完全的皮肤清除和无痒至微痒，而使用Dupixent治疗的患者只有8.9%。特应性皮炎是湿疹的一种特殊形式，是最常见的慢性炎症性皮肤病，其特点是皮肤瘙痒、干燥和发炎。2023 财年，Rinvoq 的全球销售收入为 39.7 亿美元，Dupixent 的全球销售收入为 115.9 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430047064","title":"研究显示艾伯维的 Rinvoq 优于 Regeneron 的 Dupixent","url":"https://stock-news.laohu8.com/highlight/detail?id=2430047064","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430047064?lang=zh_cn&edition=full","pubTime":"2024-04-25 20:15","pubTimestamp":1714047318,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社4月25日 - 艾伯维  周四称，其治疗一种炎症性皮肤病的药物Rinvoq在一项晚期头对头研究中显示出优于再生元制药  和赛诺菲  的Dupixent的疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429458989","title":"艾伯维公司  预计每股收益2.23美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2429458989","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429458989?lang=zh_cn&edition=full","pubTime":"2024-04-24 20:32","pubTimestamp":1713961964,"startTime":"0","endTime":"0","summary":"   * 艾伯维公司   将于4月26日公布截至2024年3月31日的季度业绩报告，预计该公司的季度收入将出现下降。   * LSEG 的分析师平均预期艾伯维公司的每股收益为 2.23 美元。该公司 2024 年 2 月 12 日发布的截至 3 月 31 日的每股收益指导值介于 2.26 和 2.30 之间。* 华尔街对艾伯维公司 12 个月目标价的中位数为 189.39 美元，高于其上次收盘价 169.54 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429129331","title":"美国疾控中心警告注射假肉毒杆菌会产生有害反应","url":"https://stock-news.laohu8.com/highlight/detail?id=2429129331","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429129331?lang=zh_cn&edition=full","pubTime":"2024-04-24 00:14","pubTimestamp":1713888884,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社4月23日 - 美国疾病控制和预防中心(CDC) 周二提醒临床医生注意艾伯维公司  的假冒肉毒杆菌毒素在多个州被用于美容目的的风险。美国疾病预防控制中心、美国食品和药物管理局(FDA) 以及州和地方合作伙伴正在调查关于注射了假冒肉毒杆菌毒素的人出现有害反应的报告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429157440","title":"专利到期 仿制药大卖导致艾伯维营收减少","url":"https://stock-news.laohu8.com/highlight/detail?id=2429157440","media":"第一财经","top":-1,"share":"https://www.laohu8.com/m/news/2429157440?lang=zh_cn&edition=full","pubTime":"2024-04-23 15:24","pubTimestamp":1713857042,"startTime":"0","endTime":"0","summary":"拥有药王“修美乐”的生物制药企业艾伯维即将公布财报，但股价连番下跌，如何看待这个企业？文章来源：第一财经原标题：专利到期 仿制药大卖导致艾伯维营收减少","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042315455687a510a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042315455687a510a8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429139311","title":"一药治三病！辉瑞(PFE.US)&艾伯维(ABBV.US)小分子疗法获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2429139311","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429139311?lang=zh_cn&edition=full","pubTime":"2024-04-23 11:25","pubTimestamp":1713842723,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，辉瑞宣布，欧盟委员会批准其与艾伯维联合开发的Emblaveo上市，用于治疗成人复杂性腹腔内感染、医院获得性肺炎，以及复杂性尿路感染。根据新闻稿，Emblaveo是首个在欧盟获批使用的β-内酰胺/β-内酰胺酶抑制剂组合，用于治疗由多重耐药革兰氏阴性菌引起的严重细菌感染成人患者。Emblaveo是aztreonam和avibactam这两种抗生素的组合。辉瑞拥有在美国和加拿大以外地区商业化该疗法的全球权利，而艾伯维则拥有Emblaveo在美国和加拿大的权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107359.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428084599","title":"艾伯维(ABBV.US)收购的Cerevel(CERE.US)达成帕金森病药物晚期阶段主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2428084599","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428084599?lang=zh_cn&edition=full","pubTime":"2024-04-18 21:25","pubTimestamp":1713446711,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾伯维的收购标的Cerevel Therapeutics周四宣布，其每日一次的帕金森病口服候选药物tavapadon在一项作为联合疗法的关键性三期试验中达成主要目标。Cerevel希望利用这些研究结果支持未来的他伐帕东监管申请。该候选药物在帕金森病中的两项后期单一疗法试验的顶线数据预计将于2024年下半年公布。去年12月，艾伯维同意以87亿美元收购Cerevel。据悉，艾伯维针对Cerevel的全现金收购预计将于2024年中期完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404182128598b3637a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404182128598b3637a2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425320311","title":"Humira生物仿制药销售滞后，勃林格将裁减销售人员","url":"https://stock-news.laohu8.com/highlight/detail?id=2425320311","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2425320311?lang=zh_cn&edition=full","pubTime":"2024-04-05 06:50","pubTimestamp":1712271031,"startTime":"0","endTime":"0","summary":" Patrick  Wingrove    路透社4月4日 - 勃林格殷格翰公司周四表示，由于艾伯维公司  的关节炎治疗大片Humira在美国的生物仿制药销售不佳，该公司将裁减部分销售人员。该公司表示，这种选择导致美国对Humira的生物仿制药的使用率降低。同期，Humira的处方量接近280万张。勃林格公司的Humira生物仿制药是第一个被美国食品和药物管理局指定为可互换的药物，这意味着它可以在不咨询处方医生的情况下替代原研药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422179635","title":"BUZZ-受艾伯维收购交易影响，兰多斯生物制药公司业绩大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2422179635","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422179635?lang=zh_cn&edition=full","pubTime":"2024-03-25 21:24","pubTimestamp":1711373062,"startTime":"0","endTime":"0","summary":"    3月25日 - ** 疗法开发商兰多斯生物制药公司  的股价盘前上涨两倍多，达到23.56美元 ** 艾伯维  将以最高2.12亿美元的价格收购该公司  ** 根据交易，ABBV将以每股20.42美元的现金收购Landos，总价约为1.375亿美元，比LABP上周五收盘价溢价160.8%。** ABBV还将向Landos股东支付每股最多11.14美元的额外里程碑付款，总额约为7500万美元。** 截至上一交易日收盘，LABP 的股价比去年同期翻了一番多","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbvie.com","stockEarnings":[{"period":"1week","weight":0.0261},{"period":"1month","weight":-0.0764},{"period":"3month","weight":-0.0289},{"period":"6month","weight":0.1582},{"period":"1year","weight":0.1115},{"period":"ytd","weight":0.0569}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.0343},{"period":"6month","weight":0.1762},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0757}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"艾伯维公司注册成立于2012年4月10日，是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法，来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域，包括类风湿性关节炎，牛皮癣和克罗恩病，银屑病和克罗恩病;低睾酮，HIV，子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.023334},{"month":2,"riseRate":0.833333,"avgChangeRate":0.030818},{"month":3,"riseRate":0.75,"avgChangeRate":0.006329},{"month":4,"riseRate":0.666667,"avgChangeRate":0.015725},{"month":5,"riseRate":0.75,"avgChangeRate":0.00749},{"month":6,"riseRate":0.454545,"avgChangeRate":0.004829},{"month":7,"riseRate":0.454545,"avgChangeRate":0.00558},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.006918},{"month":9,"riseRate":0.454545,"avgChangeRate":0.007981},{"month":10,"riseRate":0.636364,"avgChangeRate":0.011149},{"month":11,"riseRate":0.818182,"avgChangeRate":0.080758},{"month":12,"riseRate":0.727273,"avgChangeRate":0.032678}],"exchange":"NYSE","name":"艾伯维公司","nameEN":"AbbVie"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾伯维公司,ABBV,艾伯维公司股票,艾伯维公司股票老虎,艾伯维公司股票老虎国际,艾伯维公司行情,艾伯维公司股票行情,艾伯维公司股价,艾伯维公司股市,艾伯维公司股票价格,艾伯维公司股票交易,艾伯维公司股票购买,艾伯维公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}